These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 31258922)

  • 21. Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial.
    Visca D; Tsipouri V; Mori L; Firouzi A; Fleming S; Farquhar M; Leung E; Maher TM; Cullinan P; Hopkinson N; Wells AU; Banya W; Whitty JA; Adamali H; Spencer LG; Sestini P; Renzoni EA
    Trials; 2017 Apr; 18(1):201. PubMed ID: 28454553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA
    Corte TJ; Lancaster L; Swigris JJ; Maher TM; Goldin JG; Palmer SM; Suda T; Ogura T; Minnich A; Zhan X; Tirucherai GS; Elpers B; Xiao H; Watanabe H; Smith RA; Charles ED; Fischer A
    BMJ Open Respir Res; 2021 Dec; 8(1):. PubMed ID: 34969771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is It Idiopathic Pulmonary Fibrosis or Not?
    Salvatore M; Ishikawa G; Padilla M
    J Am Board Fam Med; 2018; 31(1):151-162. PubMed ID: 29330249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study.
    Wijsenbeek MS; Bendstrup E; Valenzuela C; Henry MT; Moor CC; Jouneau S; Fois AG; Moran-Mendoza O; Anees S; Mirt M; Bengus M; Gilberg F; Kirchgaessler KU; Vancheri C
    Adv Ther; 2021 Jul; 38(7):4040-4056. PubMed ID: 34117601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study.
    Scott MKD; Quinn K; Li Q; Carroll R; Warsinske H; Vallania F; Chen S; Carns MA; Aren K; Sun J; Koloms K; Lee J; Baral J; Kropski J; Zhao H; Herzog E; Martinez FJ; Moore BB; Hinchcliff M; Denny J; Kaminski N; Herazo-Maya JD; Shah NH; Khatri P
    Lancet Respir Med; 2019 Jun; 7(6):497-508. PubMed ID: 30935881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can exhaled nitric oxide differentiate causes of pulmonary fibrosis?
    Guilleminault L; Saint-Hilaire A; Favelle O; Caille A; Boissinot E; Henriet AC; Diot P; Marchand-Adam S
    Respir Med; 2013 Nov; 107(11):1789-96. PubMed ID: 24011803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnoses and treatments for participants with interstitial lung abnormalities detected in the Yorkshire Lung Screening Trial.
    Upperton S; Beirne P; Bhartia B; Boland A; Bradley C; Crosbie PAJ; Darby M; Eckert C; Gabe R; Hancock N; Kennedy MPT; Lindop J; Rogerson S; Shinkins B; Simmonds I; Sutherland TJT; Callister MEJ
    BMJ Open Respir Res; 2023 Aug; 10(1):. PubMed ID: 37612098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review: Serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease - frontiers and horizons.
    Jee AS; Sahhar J; Youssef P; Bleasel J; Adelstein S; Nguyen M; Corte TJ
    Pharmacol Ther; 2019 Oct; 202():40-52. PubMed ID: 31153954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry.
    Todd JL; Neely ML; Overton R; Durham K; Gulati M; Huang H; Roman J; Newby LK; Flaherty KR; Vinisko R; Liu Y; Roy J; Schmid R; Strobel B; Hesslinger C; Leonard TB; Noth I; Belperio JA; Palmer SM;
    Respir Res; 2019 Oct; 20(1):227. PubMed ID: 31640794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hypersensitivity pneumonitis and idiopathic pulmonary fibrosis - case report].
    Mackiewicz B; Siwiec J; Czekajska-Chehab E; Milanowski J
    Pol Merkur Lekarski; 2018 Mar; 44(261):152-156. PubMed ID: 29601568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of indoor air pollution on clinical outcomes in patients with interstitial lung disease: protocol of a multicentre prospective observational study.
    Yoon HY; Kim SY; Song JW
    BMJ Open Respir Res; 2024 Jan; 11(1):. PubMed ID: 38262669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Asbestosis: demonstration of distinctive interstitial fibroelastosis: a pilot study.
    Wick MR; Kendall TJ; Ritter JH
    Ann Diagn Pathol; 2009 Oct; 13(5):297-302. PubMed ID: 19751905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis - a potential biomarker role for LysoPC.
    Rindlisbacher B; Schmid C; Geiser T; Bovet C; Funke-Chambour M
    Respir Res; 2018 Jan; 19(1):7. PubMed ID: 29321022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral and alveolar biomarkers of fibrotic hypersensitivity pneumonitis.
    D'Alessandro M; Bergantini L; Cameli P; Landi C; Lanzarone N; Perrone A; Alonzi V; Perillo F; Bianchi F; Metella Refini R; Pieroni M; Sestini P; Bargagli E
    Panminerva Med; 2022 Dec; 64(4):548-554. PubMed ID: 33274906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Common idiopathic pulmonary fibrosis risk variants are associated with hypersensitivity pneumonitis.
    Furusawa H; Peljto AL; Walts AD; Cardwell J; Molyneaux PL; Lee JS; Fernández Pérez ER; Wolters PJ; Yang IV; Schwartz DA
    Thorax; 2022 May; 77(5):508-510. PubMed ID: 34996848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis.
    Fisher JH; Kolb M; Algamdi M; Morisset J; Johannson KA; Shapera S; Wilcox P; To T; Sadatsafavi M; Manganas H; Khalil N; Hambly N; Halayko AJ; Gershon AS; Fell CD; Cox G; Ryerson CJ
    BMC Pulm Med; 2019 Nov; 19(1):223. PubMed ID: 31771541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of Chronic Hypersensitivity Pneumonitis Biomarkers with Machine Learning and Differential Co-expression Analysis.
    Zhang H; Wang S; Huang T
    Curr Gene Ther; 2021; 21(4):299-303. PubMed ID: 33292121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and safety of nintedanib in prevention of pulmonary fibrosis induced by bleomycin in malignant ovarian germ cell tumour: study protocol for a randomised, double-blind, placebo-controlled trial.
    Li S; Zhang X; Yin M; Zhang T; Zhang R; Yang J; Yang J
    BMJ Open; 2023 Dec; 13(12):e074963. PubMed ID: 38072472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Idiopathic Pulmonary Fibrosis Registry China study (PORTRAY): protocol for a prospective, multicentre registry study.
    Xie B; Ren Y; Geng J; He X; Ban C; Wang S; Jiang D; Luo S; Chen Q; Liu M; Feng R; Zhao L; Dai H; Wang C
    BMJ Open; 2020 Nov; 10(11):e036809. PubMed ID: 33177132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Guideline Diagnosis of Fibrotic Hypersensitivity Pneumonitis in Idiopathic Pulmonary Fibrosis.
    Takei R; Yamano Y; Kataoka K; Yokoyama T; Matsuda T; Kimura T; Ozasa M; Fukuoka J; Johkoh T; Kondoh Y
    Am J Respir Crit Care Med; 2021 Sep; 204(5):603-605. PubMed ID: 34033521
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.